Literature DB >> 8629827

Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis.

I M Zonneveld1, W K Bakker, P F Dijkstra, J D Bos, R M van Soesbergen, H J Dinant.   

Abstract

BACKGROUND: In dermatology and rheumatology, methotrexate is frequently prescribed in low dosages per week; in oncology, high dosages per week are prescribed. Methotrexate osteopathy was first reported in children with leukemia treated with high doses of methotrexate. In animal studies, low doses of methotrexate proved to have an adverse effect on bone metabolism, especially on osteoblast activity. OBSERVATIONS: Methotrexate osteopathy is a relatively unknown complication of low-dose methotrexate treatment. We describe three patients treated with low-dose oral methotrexate in whom signs and symptoms were present that were similar to those found in children treated with high doses of methotrexate. All three patients had a triad of severe pain localized in the distal tibiae, osteoporosis, and compression fractures of the distal tibia, which could be identified with radiographs, technetium Tc 99m scanning, and magnetic resonance imaging.
CONCLUSIONS: Methotrexate osteopathy can occur in patients treated with low doses of methotrexate, even over a short period of time. As pain is localized in the distal tibia, it is easily misdiagnosed as psoriatic arthritis of the ankle, but the diagnosis can be correctly made by careful investigation and use of imaging techniques. The only therapy is withdrawal of methotrexate. It is important that more physicians become aware of this side effect of methotrexate therapy, which can occur along with arthritic symptoms.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8629827

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  12 in total

Review 1.  The Impact of Conventional and Biological Disease Modifying Antirheumatic Drugs on Bone Biology. Rheumatoid Arthritis as a Case Study.

Authors:  Sofia Carvalho Barreira; João Eurico Fonseca
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

Review 2.  Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?

Authors:  P Ranganathan; S Eisen; W M Yokoyama; H L McLeod
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

3.  Ubiquitous, heritable damage in cell populations that survive treatment with methotrexate.

Authors:  M Chow; H Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

4.  Influence of Rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study.

Authors:  Gert Hein; Thorsten Eidner; Peter Oelzner; Michael Rose; Alexander Wilke; Gunter Wolf; Sybille Franke
Journal:  Rheumatol Int       Date:  2010-07-27       Impact factor: 2.631

5.  The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis.

Authors:  Funda Tascioglu; Cengiz Oner; Onur Armagan
Journal:  Rheumatol Int       Date:  2003-03-21       Impact factor: 2.631

6.  Antibodies to human tissue transglutaminase and alterations of vitamin D metabolism in ankylosing spondylitis and psoriatic arthritis.

Authors:  Joachim Teichmann; Marcus J Voglau; Uwe Lange
Journal:  Rheumatol Int       Date:  2009-10-13       Impact factor: 2.631

Review 7.  Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease.

Authors:  B F Ricciardi; J Paul; A Kim; L A Russell; J M Lane
Journal:  Osteoporos Int       Date:  2012-09-07       Impact factor: 4.507

8.  No deleterious effect of low dose methotrexate on titanium implant osseointegration in a rabbit model.

Authors:  Janaina Badin Carvas; Rosa Maria Rodrigues Pereira; Eloisa Bonfá; Celey Aparecida Silveira; Luiz Lapa Lima; Valéria de Falco Caparbo; Suzana Beatriz Veríssimo de Mello
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

9.  Triads in dermatology.

Authors:  Prachi G Agrawal; Uday S Khopkar; Sunanda A Mahajan; Sunil N Mishra
Journal:  Indian J Dermatol       Date:  2013-09       Impact factor: 1.494

10.  Anti-CCP-positive patients with RA have a higher 10-year probability of fracture evaluated by FRAX®: a registry study of RA with osteoporosis/fracture.

Authors:  Tien-Tsai Cheng; Shan-Fu Yu; Fu-Mei Su; Yin-Chou Chen; Ben Yu-Jih Su; Wen-Chan Chiu; Chung-Yuan Hsu; Jia-Feng Chen; Chi-Hua Ko; Han-Ming Lai
Journal:  Arthritis Res Ther       Date:  2018-01-30       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.